Loading clinical trials...
Loading clinical trials...
A Randomized Controlled Trial to Determine the Effect of Flavor Availability on Abstinence With an Electronic Nicotine Delivery System in Primary Combustible Cigarette Smokers.
The overall purpose of this study will be to assess primary combustible cigarette users' abstinence from smoking their usual brand of combustible cigarettes at the end of the study, when provided with an electronic nicotine delivery system (ENDS) power unit (2) and varying levels of access to tobacco-flavored, menthol-flavored, or non-tobacco/non-menthol-flavored cartridge-based e-liquids (collectively referred to as the investigational product) within their assigned study arm over a three-month (ninety-day) period.
This will be a multi-site, open-label, randomized controlled trial to evaluate the rate of end-of-study abstinence of healthy adult consumers of combustible cigarettes when provided an electronic nicotine delivery system over a three-month (ninety-day) ambulatory study period. Potential participants will be recruited and enrolled at 27 sites across the United States. Ipsos will recruit participants in person (e.g., through mall intercepts) at each site or by telephone from existing databases of previous research participants. Based on meeting eligibility requirements, participants will be required to read and sign an Informed Consent Form and to attend a site visit to complete enrollment. At the Enrollment Visit, participants will be randomized to one of the three study arms. All participants will begin the study with a one-week Trial Period. This Trial Period will allow participants to sample the available flavor(s) within their assigned study arm. All participants will attend mandatory follow-up site visits on Day 0, Day 30, Day 60, and Day 90, with the option of changing to a different flavor among the available flavors based upon their assigned study arm, if applicable. In the first four weeks of the study, participants in Study Arms 1 and 2 may also attend optional site visits on Day 7, Day 14, and Day 21, with the option of changing flavors among those available in their assigned study arm. All site visits will record the number of study investigational product cartridges dispensed, in addition to all used and unused investigational product cartridges returned. During the three-month ambulatory study period, participants will be free to use the study investigational product and any other tobacco or nicotine products as desired. The electronic nicotine delivery system (Version 2) power unit technology will measure their puffing topography during use (including puff duration and the time interval between puffs). The puffing topography data will be automatically transferred to a secure online database via a Bluetooth transfer application using the provided smartphone. Participants will be invited to complete daily, weekly, and monthly surveys, using a mobile application installed on the provided smartphone. Surveys will collect data on: 1. The number of cigarettes smoked the previous day 2. Current flavor use 3. Product liking 4. Number of cigarette quit attempts 5. Use of other tobacco or nicotine products 6. Intent to substitute their usual brand combustible cigarettes for the study investigational product (e.g., gradual, complete, or future intent) 7. Social and environmental factors influencing switching intent At the conclusion of the ambulatory study period, all participants will return to the study sites for a close-out period and will then be discharged from the study.
Age
21 - 65 years
Sex
ALL
Healthy Volunteers
Yes
CRG Test America-Phoenix
Chandler, Arizona, United States
C&C-Fort Smith
Fort Smith, Arkansas, United States
Research America Orlando
Altamonte Springs, Florida, United States
C&C-Tampa
Clearwater, Florida, United States
Sago Orlando
Maitland, Florida, United States
CRG Test America-Pembroke Pines
Miami, Florida, United States
CRG Test America-Ormond Beach
Ormond Beach, Florida, United States
C&C-Plantation
Plantation, Florida, United States
C&C-Sebring
Sebring, Florida, United States
C&C-Tallahassee
Tallahassee, Florida, United States
Start Date
September 17, 2025
Primary Completion Date
January 14, 2026
Completion Date
January 14, 2026
Last Updated
February 27, 2026
668
ACTUAL participants
P2611222
OTHER
P2615022
OTHER
P2615122
OTHER
P2613422
OTHER
Lead Sponsor
RAI Services Company
NCT06372899
NCT07441928
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions